Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00852137 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
A Phase 2 study, sponsored by Peplin.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00852137 is a Phase 2 study that has completed, run by Peplin. The registered enrollment target is 16 participants.
The verdict
NCT00852137, a Phase 2 study, has completed, sponsored by Peplin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses
Interventions
- DRUG Vehicle Gel
- DRUG PEP005 (ingenol mebutate) Gel, 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00852137
The ClinicalTrials.gov registry entry for NCT00852137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peplin, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Gel is the first listed.
NCT00852137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00852137 about?
NCT00852137 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis". This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses
What is the current status of trial NCT00852137?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2009-03. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00852137?
The interventions under investigation include: Vehicle Gel (DRUG), PEP005 (ingenol mebutate) Gel, 0.05% (DRUG).
Who is sponsoring clinical trial NCT00852137?
This trial is sponsored by Peplin, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.